Regional distribution of genetic mutation in lung cancer in Turkey (REDIGMA)

Özçelik, Neslihan; Bülbül, Yılmaz; ERDOĞAN, Yurnadur; Güldaval, Filiz; Gül, Şule Karabulut; Bircan, Ahmet; Can, Atilla; Öz, Necdet; Şentürk, Ayşegül; Arınç, Sibel; Kılıç, Talat; Kurt, Emine Bahar; Günay, Ersin; Çağlayan, Benan; AYDIN, Derya Çelebi; Başyiğit, İlknur; Savaş, İsmail; Alizoroglu, Dursun; Arslan, Sülhattin; Kömürcüoğlu, Berna; Bayram, Mehmet; Gülmez, İnci; Doğan, Ömer Tamer; Niksarlıoğlu, Elif Yelda; Kaba, Erkan; Karaoğlanoğlu, Selen; Özgür, Esra Aydın; Özçelik, Ali Erdem; Özlü, Tevfik

doi:10.5578/tt.68707

Cited by 5 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One study from Turkey (703 patients) did not mention specific exons genotyped. 20 A wide variety of detection methods were used to identify mutations of the EGFR kinase domain. Direct sequencing was broadly used, as it was used in 7 of the included studies.…”

Section: Resultsmentioning

confidence: 99%

“…Of the 30 publications, 24 studies were selected after the elimination of redundancies. These articles were assessed for eligibility and 15 studies were selected for this review: 11 (73.3%) from the Middle East [16][17][18][19][20][21][22][23][24][25][26] and 4 (26.6%) in North Africa. [27][28][29][30] Original articles were identified from Jordan, 16 Iran, 17 Turkey, [18][19][20] Iraq, 22 Lebanon, [23][24][25] Morocco, [27][28][29] and Egypt.…”

Section: Literature Researchmentioning

confidence: 99%

“…These articles were assessed for eligibility and 15 studies were selected for this review: 11 (73.3%) from the Middle East [16][17][18][19][20][21][22][23][24][25][26] and 4 (26.6%) in North Africa. [27][28][29][30] Original articles were identified from Jordan, 16 Iran, 17 Turkey, [18][19][20] Iraq, 22 Lebanon, [23][24][25] Morocco, [27][28][29] and Egypt. 30 A multicenter prospective study from the Levant (Lebanone, Syria, Palestine, Jordan, Iraq, and Egypt) 26 and a multisite retrospective study from the Gulf (Saudi Arabia, the United Arab Emirates and Qatar) were also identified and will be part of our analysis.…”

Section: Literature Researchmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence and Patterns of EGFR Mutations in Non-small Cell Lung Cancer in the Middle East and North Africa

et al. 2022

View full text Add to dashboard Cite

Objectives This study aims to analyze the prevalence and spectrum of epidermal growth factor receptor (EGFR) mutations within the Middle East and North Africa region, compare the findings to other parts of the world, and explore the geographic disparities of EGFR mutations across the region. Methods We conducted a literature search using the terms “[EGFR] AND [mutation] AND [Non-Small Cell Lung Cancer] AND [Middle East OR North Africa]”, using PubMed, Science Direct, Web of science, Embase, Scopus, and Google scholar. Results A total of 15 eligible studies were included and 6122 patients with non-small cell lung cancer (NSCLC) were analyzed. Male patients were predominant in all of the considered studies, accounting for 70.4%. Of the included patients, 65.6% were smokers and 88.3% had been diagnosed with adenocarcinoma. Overall, EGFR mutations prevalence was 17.2%. In the Middle East, the reported frequency was 16.5%, ranging from 11.3% in Lebanon to 29.7% in the Gulf region. In North Africa, the prevalence of EGFR mutations was 18%, ranging from 17.5% in Egypt to 21.5% in Morocco. The most prevalent mutations were the exon 19 deletions (46.7%) followed by exon 21 substitutions (31.1%). Exon 20 alterations were detected in 10.8% of the analyzed cases, whereas exon 18 mutations were reported in 3.4% of the EGFR-mutated patients. There was 1.1% of patients that had concurrent EGFR mutations. Overall, EGFR mutation prevalence was higher in females [females vs males: 29.7% vs 5.9%, P<.001], non-smokers [non-smokers vs smokers: 31.3% vs 9.6%, P<.001], and patients with adenocarcinoma [adenocarcinoma vs non-adenocarcinoma: 18.8% vs 6.5%, P<.001]. Conclusion EGFR mutation prevalence among the Middle East and North Africa populations is slightly higher than that seen in NSCLC patients of Caucasian ethnicity but is lower than that identified in Asian NSCLC patients. The distribution of these mutations varies considerably throughout the region.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Literature Researchmentioning

confidence: 99%

Section: Literature Researchmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and Patterns of EGFR Mutations in Non-small Cell Lung Cancer in the Middle East and North Africa

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Мутации в гене EGFR выявлены в 69,9%, ALK -у 26,3%, ROS1 у 1,6% пациентов, а PDL-1 только в 2,2%. У женщин частота мутаций выше [12].…”

Section: результаты и обсуждениеunclassified

“…Среди мутаций на долю EGFR приходилось 69,9%, ALK -26,3%, ROS1 -1,6% и PDL-1 -2,2%, причем отмечалось их преобладание у женщин и при аденокарциноме. Различий мутаций по возрасту, клинической стадии и местам проживания не получено [12].…”

Section: Introductionunclassified

Molecular genetic portrait of non-small cell lung cancer in Tambov region: regional experience

et al. 2020

View full text Add to dashboard Cite

8090%. The identification of gene mutation profile of non-small cell cancer allows to make a molecular portrait, which plays the crucial role in choosing the targeted therapy with tyrosine kinase inhibitors. The aimis to study the frequency and spectrum of activating mutations in non-small cell lung cancer in Tambov region. The study of the presence of mutations and the main driver gene mutation profile: EGFR, ALK, BRAF, ROS1 and PDL-1 using sections of paraffin-embedded after the surgery and biopsy in 238 patients with the help of polymerase chain reaction and immunohistochemistry. The age of patients ranged from 28 years to 82 years, with a mean age of 60.3 years. Results.Adenocarcinoma was detected in 80.3% of patients, and squamous cell variant in 19.7% of cases. The frequency of the driver gene activating mutations in non-small cell lung cancer was 29%, this index exceeded the frequency in the European population. Statistically significant predominance of female (63.6%) vs male (36.4%) was achieved. The mutation frequency increases with age. In this case, EGFR mutations were observed more often 22.3%. This index was slightly higher than in the European population. Statistically significant predominance of female was achieved. The highest frequency of mutations was demonstrated in patients 6570 years of age (24%). The deletion of exon 19 and single-nucleotide replacement L858R of exon 21 were observed in 54.5% and 45.5% of cases, respectively. The mutation of exon 19 was more often detected in male, at the same time the mutations of exons 19 and 21 in female were detected in almost the same frequency. Maximum frequency mutation rate (77.7%) in the EGFR gene was detected free from metastases to the regional lymph nodes. ALK mutations were found in 14.6% of patients, this index was slightly higher than the European level. PDL-1 expression is found in 40% male patients. Conclusion.The results of the study revealed some features of the profile of activating mutations in non-small cell lung cancer in the region. This data should be taken into account on planning and applying targeted therapy.

show abstract